Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access |
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc |
Journal website http://www.jofem.org |
Original Article
Volume 7, Number 2, April 2017, pages 61-67
Glycemic Control Rate in Type 2 Diabetes Mellitus Patients at a Public Referral Hospital in Rio de Janeiro, Brazil: Demographic and Clinical Factors
Tables
Variables | Total, n (%) |
---|---|
aAge, patient’s age obtained at last evaluation. bFormer practice no longer present in the last medical visit. T2D: type 2 diabetes; CKD: chronic kidney disease; OAD: oral antidiabetic medication; BMI: body mass index; HbA1c: glycated hemoglobin. | |
Male/female | 321 (32.0%)/680 (68.0%) |
Agea (years) | 61 (21 - 95) |
Diabetes duration (years) | 10 (1 - 58) |
T2D family history (n = 527) | 352 (66.8%) |
Smoking (n = 639) | |
Passedb/present | 236 (37.0%)/69 (10.8%) |
Alcohol consumption (n = 589) | |
Previousb/Present | 48 (8.1%)/11 (1.8%) |
Hypertension | 812 (81.1%) |
Dyslipidemia | 751 (75.0%) |
CKD | 185 (18.5%) |
Treatment | |
Only OAD | 460 (46.0%) |
OAD + insulin | 363 (36.3%) |
Only basal insulin | 54 (5.4%) |
Basal + bolus insulin | 102 (10.2%) |
Nutritional follow-up (n = 898) | 331 (36.9%) |
Waist circumference (cm) (n = 206) | 100 (72 - 150) |
BMI (kg/m2) | 29.50 (16.17 - 57.00) |
Overweight/obesity | 223 (22.3%)/302 (30.2%) |
HbA1c (%) | 7.3 (4.3 - 15.2) |
Variables | HbA1c < targeta (n = 510; 51.0%) | HbA1c > targeta (n = 491; 49.0%) | P-value |
---|---|---|---|
aFor this analysis, we considered ADA’s goals for T2D patients as: HbA1c < 7.0% for young adults and < 8.0% for older than 70 years old, with serious microvascular or macrovascular complications, presence of severe hypoglycemia or several comorbidities, or with a limited life expectancy. bAge at last consultation. cFormer practice no longer present in the last medical visit. dIntermediate insulin (NPH) or long-acting analogues. eRapid insulin (regular) or ultra-rapid acting analogues. T2D: type 2 diabetes; CKD: chronic kidney disease; HbA1c: glycated hemoglobin; NS: not significant; OAD: oral antidiabetic medication. | |||
Male/female | 53.0%/50.0% | 47.0%/50.0% | NS |
Ageb (years) | 64 (33 - 95) | 59 (21 - 91) | < 0.001 |
Diabetes duration (years) | 10 (1 - 58) | 11 (1 - 46) | 0.057 |
T2D family history (n = 527) | 45.5% | 54.5% | 0.042 |
Previousc/present smoking (n = 639) | 53.8%/43.5% | 46.2%/56.5% | NS |
Previousc/present alcohol consumption (n = 589) | 70.8%/36.4% | 29.2%/63.6% | 0.006 |
Hypertension | 53.2% | 46.8% | 0.003 |
Dyslipidemia | 52.1% | 43.0% | NS |
CKD | 60.5% | 39.5% | 0.004 |
Overweight | 45.7% | 54.3% | < 0.001 |
Obesity | 42.4% | 56.6% | < 0.001 |
Treatment | |||
Only OAD | 66.7% | 33.3% | < 0.001 |
OAD + insulin | 33.8% | 66.2% | < 0.001 |
Only basald insulin | 49.0% | 51.0% | NS |
Basal + boluse insulin | 37.8% | 62.2% | 0.006 |
HbA1c (%) | 6.3 (4.3 - 7.9) | 8.7 (7.0 - 15.2) | < 0.001 |